Revised forecast
Fiscal year ending March 2026 · Full yearPrevious forecast published 15 May 2025The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
The cost-of-sales ratio increased due to a shift in demand in the arrhythmia field resulting from the adoption of PFA-related products and changes in the product mix. In addition, increases in various expenses due to rising prices, as well as higher-than-planned costs for outsourcing and personnel, including recruitment expenses, exceeded the plan.
| Item | Details |
|---|---|
| Net Sales | ¥51,956 million → ¥55,989 million（+7.8%） |
| Operating profit | ¥581 million → ¥279 million（-51.9%） |
| Ordinary income | ¥581 million → ¥299 million（-48.5%） |
| Profit attributable to owners of the parent | ¥395 million → ¥189 million（-51.9%） |
| Net income per share | 37.66 yen → 18.1 yen |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 15 May 2025 |
| Previous-period results | Full-year fiscal year ended March 2025: net sales ¥50,321 million, operating profit ¥537 million, ordinary profit ¥542 million, net income attributable to owners of the parent ¥410 million, net income per share ¥39.20 |
| Reason for the revision | The cost-of-sales ratio increased due to a shift in demand in the arrhythmia field resulting from the adoption of PFA-related products and changes in the product mix. In addition, increases in various expenses due to rising prices, as well as higher-than-planned costs for outsourcing and personnel, including recruitment expenses, exceeded the plan. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Demand shifted in the arrhythmia field as the adoption of PFA-related products exceeded expectations, and changes in the product mix resulted in a higher cost-of-sales ratio. In addition, increases in various expenses due to rising prices, as well as higher-than-planned costs for outsourcing and personnel, including recruitment expenses incurred in anticipation of future growth, exceeded the plan.